AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:16 18/06/2025 BST			5-day change	1st Jan Change
10,548.00 ^GBX	-1.07%		-2.98%	+0.76%

06-02	ASTRAZENECA : Buy rating from JP Morgan	ZD
06-02	UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	RE

ASTRAZENECA : JP Morgan reaffirms its Buy rating

Published on 10/07/2024 at 06:43, updated on 10/07/2024 at 07:30

In a research note published by James Gordon, JP Morgan advises its customers to buy the stock. The target price is unchanged and still at GBX 13000.

Latest news about AstraZeneca PLC

ASTRAZENECA : Buy rating from JP Morgan	06-02	ZD
UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	06-02	RE
UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	06-02	RE
Global markets live: Tesla, Sanofi, Apple, JPMorgan, Microsoft…	06-02
AstraZeneca says Enhertu slashes disease progression risk in cancer	06-02	AN
AstraZeneca Says DATROWAY Shows Promising Results in Combination Trials for Lung Cancer	06-02	MT
AstraZeneca, Daiichi Sankyo's Gastric Cancer Phase 3 Trial Shows 'Statistically Significant' Improvement in Overall Survival	06-02	MT
Hutchmed reports progress in late-stage lung cancer trial	06-02	AN
AstraZeneca: promising results for Imfinzi in gastric cancer	06-02	CF
AstraZeneca Says Imfinzi Combo Boosts Event-Free Survival in Gastric Cancer Trial	06-02	MT
AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial	06-02	MT
AstraZeneca: camizestrant effective in breast cancer	06-02	CF
ASTRAZENECA : Receives a Buy rating from JP Morgan	06-02	ZD
Stocks edge down as renewed trade tensions continue	06-02	AN
AstraZeneca hails Imfinzi results on early stage gastric cancer	06-02	AN
AstraZeneca's Breast Cancer Treatment Extends Progression-free Survival in Late-stage Trial	06-02	MT
AstraZeneca Reports Positive Phase 3 Data for Imfinzi Regimen for Early-stage Gastric Cancer	06-02	MT
PRESS DIGEST- Financial Times - June 2	06-02	RE
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk	06-01	RE
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk	06-01	RE
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial	06-01	RE
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression	05-31	RE
FTSE 100 rises despite tariff worries; M&G shines	05-30	AN
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools	05-30	MT
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy	05-30	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

18/06/2025 - J.P. Morgan European Healthcare Forum

More about the company